Jonathan Katz, MD
Glaucoma Specialist · Lutherville, MDNPI 1447678487
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,812 of the $10,202 with a category attached, or 66.8%. 26 manufacturers reported payments, led by Glaukos Corporation at 36.0% of the total. Reporting peaked in 2024 at $4,211 and has fallen 72.9% since, to $1,140 in 2025.
Across 174 payments — averaging $58.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$4K
- Sight Sciences, Inc.$2K
- Alcon$1K
- AbbVie$811
- NEW World Medical,inc.$619
- Alcon Research LLC$558
- plus $2K from 20 others
What the payments were for
- Consulting fees$2,85828%
- Speaking & faculty fees$4444%
- Food & beverage$6,81267%
- Education$70%
- Gifts$821%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 18 | $3,672 |
| Sight Sciences, Inc. | 32 | $1,588 |
| Alcon | 35 | $1,138 |
| AbbVie(2 entities) | 37 | $811 |
| NEW World Medical,inc. | 4 | $619 |
| Alcon Research LLC | 1 | $558 |
| Notal Vision, Inc. | 1 | $444 |
| Aerie Pharmaceuticals, Inc. | 7 | $300 |
| Trice Medical, Inc. | 1 | $219 |
| Bausch & Lomb Americas Inc. | 7 | $121 |
| Acumed LLC | 1 | $110 |
| Tarsus Pharmaceuticals, Inc. | 3 | $105 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $74 |
| Eyepoint US, Inc. | 3 | $73 |
| Oyster Point Pharma, Inc. | 4 | $72 |
| Thea Pharma Inc. | 3 | $61 |
| Omeros Corporation | 3 | $51 |
| Dompe US, Inc. | 1 | $31 |
| Apellis Pharmaceuticals, Inc. | 1 | $30 |
| Rayner Intraocular Lenses Limited | 1 | $27 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Harrow Eye, LLC | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Ocular Therapeutix, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$1,237
- Hydrus Microstent$659
- Segway blade or mieye camera$219
- Clareon$146
- iStent inject W$145
- Rocklatan$125
- Rhopressa$125
- iStent Trabecular Micro-Bypass Stent System$125
- iStent inject Trabecular Micro-Bypass Stent System$125
- Kahook Dual Blade$124
- Clearpath$124
- Ahmed Glaucoma Valve$124
- Streamline$124
- Via360$124
- Photrexa$120
- SION SURGICAL INSTRUMENT$116
- iDoseTR$115
- iDose$114
- NGENUITY$113
- Acu-Loc/Acu-Loc 2 Wrist Plating System$110
How this compares
Too few glaucoma specialist providers in Marylandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 294 | $176,944 |
| RocklatanNetarsudil Mesylat/Latanoprost | 320 | $161,240 |
| CombiganBrimonidine Tartrate/Timolol | 113 | $53,274 |
| RhopressaNetarsudil Mesylate | 82 | $49,869 |
| Latanoprost | 1,828 | $29,397 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,009 | $23,676 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 123 | $23,502 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 80 | $22,255 |
| Travoprost | 116 | $20,590 |
| Prednisolone Acetate | 372 | $17,013 |
| RestasisCyclosporine | 17 | $12,257 |
| Timolol Maleate | 342 | $10,580 |
| Brinzolamide | 35 | $10,042 |
| VyzultaLatanoprostene Bunod | 22 | $9,296 |
| Travatan ZTravoprost | 15 | $8,672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis | $811 | $242,475424 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $300 | $211,109402 claims |
| AlconSimbrinza | $1,138 | $22,25580 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $121 | $9,29622 claims |
| NovartisTravatan Z | $16 | $8,67215 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $74 | $1,55813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Marylandon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Lutherville
- Osamah SaeediBaltimore$10K
- Alanna JamesBowie$5K
- Heather NestiAnnapolis$5K
- Russell HuangBethesda$3K
- Katherine FallanoBaltimore$2K
- Teresa HoranBaltimore$2K
- Lisa TomChevy Chase$2K
- Alexander Baten-TschanBethesda$2K
- Lindsay DawsonChevy Chase$2K
- Elyse McGlumphyBaltimore$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.